NF-κB and Hypoxia A Double-Edged Sword in Atherosclerosis by Sun, Xinghui & Feinberg, Mark W.
See related article on page 1530
The American Journal of Pathology, Vol. 181, No. 5, November 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.09.001Commentary
NF-B and HypoxiaA Double-Edged Sword in AtherosclerosisXinghui Sun and Mark W. Feinberg
From the Cardiovascular Division, Department of Medicine,
Brigham and Women’s Hospital, Harvard Medical School,
Boston, Massachusetts
Hypoxia, a decrease in oxygen tension within tissues,
occurs in response to several pathophysiological disease
states, including myocardial ischemia, atherosclerosis,
and obstructive sleep apnea. HIF-1, a basic helix-loop-
helix transcription factor and a master regulator of cellular
homeostatic responses to hypoxia, activates transcrip-
tion of genes involved in energy metabolism, angiogen-
esis, apoptosis, and cell differentiation. HIF-1 is regu-
lated post-transcriptionally by prolyl hydroxylases under
normoxic conditions, an effect that allows for their recog-
nition and ubiquitination by the von Hippel-Lindau E3
ubiquitin ligase and rapid degradation by the protea-
some.1–3 However, accumulating data indicate that
HIF-1 may also be regulated in response to inflamma-
tory stimuli in an NF-B–dependent manner.4,5 The inter-
play between hypoxia and inflammation, along with its
pathological role in acute and chronic inflammatory dis-
ease states such as atherosclerosis, has emerged as a
subject of significant scientific interest.6
Chronic Intermittent Hypoxia and
Atherosclerosis
Obstructive sleep apnea (OSA), characterized by
chronic intermittent hypoxia (CIH) as a result of repetitive
episodes of complete or partial obstructions of the upper
airway during sleep, is an independent risk factor for the
development of cardiovascular disease. Furthermore, the
prevalence of OSA has been estimated to be as high as
50% in persons with cardiometabolic disorders.7 Athero-
sclerosis, a chronic inflammatory disease of the arterial
wall, develops in a more aggressive manner in the con-
text of OSA.8,9 Experimentally, CIH initiates atherosclero-
sis in the presence of high-fat, diet-induced dyslipidemia
in both wild-type C57BL/6J mice10 and atherosclerotic-
prone ApoE knockout (ApoE-KO) mice,11 effects that es-tablished a causal link between CIH and atherosclerosis.
More recent studies suggest that RANTES/CCL5 signal-
ing, leukotriene B4 pathway activation, and several other
inflammatory components contribute to CIH-induced ath-
erosclerosis.12–14 Despite these observations, the mech-
anisms by which outside-in hypoxic signaling acceler-
ates the initiation and progression of atherosclerosis are
poorly understood, in part because of the limitations of
current animal models for CIH-induced atherosclerosis;
such models typically involve exposure to CIH in animals
with pre-existing atherosclerotic pathology, potentially
obscuring the initiation phase of lesion development. Fur-
thermore, because activation of NF-B (particularly in the
vascular endothelium) has been linked to increased ath-
erosclerotic lesion formation, it has been hypothesized
that the loss of NF-B family members may reduce ath-
erosclerosis, including atherosclerosis in response to
CIH. In this issue, Fang et al15 report development of two
new mouse models of CIH-induced atherosclerosis; their
study, surprisingly, revealed that loss of the NF-B p50
subunit increased atherosclerosis in the presence of CIH.
In the first model, ApoE-KO mice were fed a normal
chow diet and exposed to CIH. After 9 weeks of CIH
exposure, no obvious lesions were observed in the tho-
racic and abdominal aorta, compared with sham-ex-
posed ApoE-KO mice; a trend toward increased num-
bers of lesions in the aortic root did not reach
significance. After 30 weeks of CIH exposure, however,
atherosclerotic lesion areas increased in both the aortic
root and the thoracic-abdominal aorta. Importantly, lesion
areas of ApoE-KO mice given a high-fat diet were ap-
proximately threefold greater than in CIH-exposed
ApoE-KO mice, suggesting that CIH is a much weaker
physiological stimulus for atherosclerotic lesion forma-
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AJP November 2012, Vol. 181, No. 5tion, compared with dyslipidemia. In the second model,
compound ApoE and p50 double-knock-out mice (ApoE-
p50-DKO) were fed a normal chow diet and exposed
to CIH. Remarkably, after 9 weeks of CIH exposure, ath-
erosclerotic lesion formation increased approximately
2.5-fold in ApoE-p50-DKO mice, compared with CIH-
exposed ApoE-KO mice. Thus, ApoE-KO mice with sys-
temic deficiency of p50 are more sensitive to CIH-
induced atherogenesis, suggesting an atheroprotective
role of the NF-B p50 subunit in the presence of CIH.
Examination of the NF-B signaling pathway revealed
a reduction in IB expression in CIH-ApoE-KO mice,
indicating activation of the canonical NF-B pathway.
Interestingly, supershift assays of NF-B DNA-protein
binding showed that the CIH-induced NF-B complex in
ApoE-KO mice is composed predominantly of p50/p50
homodimers, with minor contributions from c-Rel/p50 and
likely also p65/p50 heterodimers. NF-B DNA-binding
was severely decreased by p50 gene deletion in
ApoE-KO mice, particularly in response to CIH (Figure 1).
Importantly, the expression of the proinflammatory NF-B
target genes TNF, IL6, and NOS2 (encoding TNF-, IL-6,
and iNOS, respectively) was increased by CIH, and
NF-B p50 deletion further increased their expression, an
effect that was associated with aortic accumulation of
Mac3-positive macrophages.
Nonetheless, some caution is indicated in interpreting
the accelerated atherosclerotic phenotype in ApoE-p50-
DKO mice, given that these mice exhibited increased
serum total cholesterol levels. Such increased serum total
cholesterol levels can potentially contribute to lesion for-
mation through excessive intralesional macrophage
foam-cell formation, among other mechanisms. Although
the mechanism by which p50 deficiency increases total
cholesterol remains unclear (despite absence of
changes in LDL, HDL, or triglyceride fractions), mRNA
expression of hepatic LDL receptor, which participates in
LDL-mediated cholesterol uptake and clearance, was
significantly reduced. Further studies will be required to
determine how p50 regulates LDL receptor expression
Figure 1. NF-B p50 protects ApoE-KO mice from CIH-induced atheroscler
p65/p50 and c-Rel/p50 heterodimers bind to NF-B-responsive targets and i
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thereby further increasing expression of TNF-, IL-6, and iNOS. However, d
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p50-DKO mice. Nevertheless, the study by Fang et al15
provides a mechanistic understanding of how outside-in
hypoxia signaling promotes atherosclerosis, without the
limitations of prior models confounded by pre-existing
atherosclerosis. Although their study revealed a protec-
tive role of NF-B p50 in CIH-induced atherosclerosis, the
initiating events linking hypoxia to NF-B–mediated in-
flammation remain incompletely understood.
NF-B and Hypoxia
Emerging studies have revealed several mechanistic
paradigms that link NF-B and hypoxia signaling path-
ways. The NF-B transcription factor family consists of
five members: RelA, RelB, c-Rel, p50, and p52. RelA,
RelB, and c-Rel contain a C-terminal transactivation do-
main, but no definable activation domains are found in
p50 and p52. NF-B p50 is processed from its precursor
p105. The precursor p105 functions as an NF-B inhibi-
tor, blocking the activity of its dimeric NF-B partners and
retaining them in the cytoplasm. The NF-B family mem-
bers can form different homo- and heterodimers, with
each dimer being involved in the regulation of a unique
set of target genes. The p65/p50 heterodimer, which
represents the most abundant NF-B dimer, is activated
in response to proinflammatory stimuli (such as TNF-,
IL-1, and LPS) in almost all cell types through the ca-
nonical NF-B signaling pathway. RelB/p52 heterodimers
are activated by lymphotoxin, B-cell activating factor, or
CD40 ligand via the noncanonical NF-B pathway, which
involves inducible proteolytic removal of the ankyrin-re-
peat domain of p100/RelB heterodimers. Several other
heterodimers containing p50 have been described, in-
cluding p50/c-Rel, p50/p50, and p50/RelB. For example,
p50/c-Rel heterodimers are the primary component of
constitutively active NF-B observed in mature B cells.
However, not all NF-B dimers are transcriptionally ac-
tive; in particular, p50/p50 homodimers have been found
der normoxic conditions in ApoE-KO mice (left panel), translocated NF-B
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binding to B sites in unstimulated or resting cells.16
Alternatively, p50 may interact with histone deacetylases
or other coregulators that inhibit an activator of target
genes.17–19 Indeed, p50/p50 homodimers repress the
expression of NF-B target genes, such as those encod-
ing TNF-, IL-6, and IL-8.20–22 For example, during pro-
longed exposure to LPS, the binding of p50 homodimers
to the B sites at the TNF- promoter reduced transcrip-
tional activation and blocked the production of TNF-.23
Consistent with these reports, Fang et al15 found that
TNF-, IL-6, and iNOS were induced in CIH-exposed
ApoE-KO mice and that the induction was further poten-
tiated in the absence of p50, suggesting that p50 plays a
suppressive function for the gene expression of these
proteins in response to CIH. These data also imply that
the relative ratio of endogenous NF-B subunits is critical
for selective gene expression (Figure 1). Interestingly,
although they found that the CIH-induced NF-B complex
is composed primarily of p50/p50 homodimers, small
amounts of c-Rel/p50 and likely also p65/p50 het-
erodimers remain. Consequently, loss of transcriptionally
repressive p50 may allow for increased heterodimeriza-
tion and transcriptional activity of c-Rel/p50 or p65/p50
heterodimers on NF-B–responsive promoters to induce
TNF-, IL-6, and iNOS expression in response to CIH.
Accumulating data from several studies indicate sig-
nificant crosstalk between the HIF-1 and NF-B signaling
pathways. In response to hypoxia, the canonical NF-B
pathway is activated, in part, by inhibition of prolyl hy-
droxylases that negatively regulate IKK activity. Modest
IKK activation by hypoxia leads to IB phosphorylation
and degradation, followed by NF-B p65 nuclear trans-
location, binding to B elements, and induction of gene
expression.5,24 A further level of crosstalk between hyp-
oxia and NF-B has been reported, whereby HIF-1 can
regulate NF-B signaling through up-regulation of p65
and IKK in neutrophils.25 Conversely, NF-B is able to
bind the HIF-1 promoter and induce its expression in
vitro and in vivo under hypoxic or normoxic conditions.5
Thus, it would be interesting to investigate whether loss of
NF-B p50 alters HIF-1 promoter and expression in
response to CIH in atherosclerotic-prone mice.
Is NF-B p50 a Good Actor or Bad Actor in
Inflammation?
The NF-B p50 systemic knockout mice exhibit no devel-
opmental abnormalities at birth; adults, however, pos-
sess defects in immune responses involving B lympho-
cytes, development of LPS tolerance, skeletal muscle
atrophy, and severe colitis after Helicobacter hepaticus
infection.23,26,27 NF-B p50 also plays a protective role in
neurovascular development, cell survival, aging in the
central nervous system, and development of Hunting-
ton’s disease.28,29 In the study by Fang et al,15 p50
deficiency potentiated CIH-induced atherosclerosis in
ApoE-KO mice. Cell-type–specific effects of p50 defi-
ciency in the context of CIH-induced atherosclerosis will
have to be sorted out in future studies. For example,differentiated macrophages can be categorized into two
broad types, M1 and M2, based on both expression and
function of cytokines. Porta et al30 identified p50 as a key
regulator of M2-driven inflammatory reactions. In that study,
p50 inhibited NF-B–driven M1 polarization and IFN- pro-
duction; conversely, p50-deficient mice showed exacer-
bated M1-driven inflammation and defective capacity to
mount allergy and helminth-driven M2-polarized inflamma-
tory reactions. The p50-deficient macrophages also dis-
played impaired expression of M2-related genes for IL-10,
TGF-, CCL2, CCL17, CCL22, and type I arginase. Thus,
p50 is a negative regulator of M1-associated gene ex-
pression (TNF-, iNOS, and IFN-), but it plays a nonre-
dundant positive role in induction of M2-associated
genes. In this light, the findings by Fang et al15 of in-
creased circulating or lesional expression of TNF-, IL-6,
and iNOS in CIH-exposed ApoE-p50-DKO mice are con-
sistent with this premise and raise the possibility that the
ratio of M1 to M2 macrophages may contribute to the
phenotype.
Loss of p50, however, may be a double-edged sword
in other relevant conditions associated with atherosclero-
sis. For example, p50-KO mice were protected from
streptozotocin-induced diabetes, had less damage in re-
sponse to focal cerebral ischemia, and had reduced
ischemia-reperfusion injury revealed by smaller myocar-
dial infarction size in vivo, an effect associated with less
neutrophil infiltration despite increased ICAM-1 expres-
sion.31 Furthermore, p50-KO mice develop less left ven-
tricular dilation and have reduced early mortality after
coronary artery ligation than wild-type mice.32 Thus,
NF-B signaling appears to have divergent functions that
can exhibit either protective or detrimental effects on
cardiovascular tissues, depending on the cellular and
pathophysiological context. Given that myocardial infarc-
tion and stroke are major complications of atherosclero-
sis, further studies are merited to establish the precise
role of NF-B p50 and to determine whether increasing
p50 in a cell-specific manner may confer a beneficial
effect in atherosclerosis and CIH without affecting tissue
injury.
NF-B and Atherosclerosis
Brand et al33 detected activation of NF-B in human
vascular smooth muscle cells, macrophages, and endo-
thelial cells in the fibrotic-thickened tunica intima/media
and atheromatous areas of lesions, but not in vessels
lacking atherosclerosis. Activated NF-B was also de-
tected in intimal cells in coronary arteries of pigs with a
hypercholesterolemic diet34 and in aortic endothelial
cells in LDLR knockout mice after 2 weeks of a choles-
terol-enriched diet.35 Indeed, NF-B downstream target
genes, including those for VCAM-1 and ICAM-1, were
up-regulated in response to hypercholesterolemia at
sites predisposed to atherosclerotic lesion formation.36 In
addition to dyslipidemia, many atherogenic risk factors
activate NF-B, including bacterial and viral infection,
hemodynamic shear-stress forces, angiotensin II, and
advanced glycation end products.35,37–39 A causal link
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erosclerosis was experimentally validated in vivo by Ga-
reus et al,40 based on several mouse models with endo-
thelial cell-specific NF-B inhibition. These studies
revealed that i) endothelial cell-specific NF-B IKK ab-
lation leads to a 30% reduction in atherosclerotic lesion
size, ii) inducible IKK ablation reduced atherosclerosis
by 33% in males and 47% in females, and iii) endothelial
dominant-negative IB expression reduced atheroscle-
rotic plaque area by 60%.
Although it is clear that endothelial NF-B activation
promotes the initiation and progression of atherosclero-
sis, the role of myeloid NF-B signaling in atherosclerosis
remains unclear. NF-B plays an important role in cell
survival. Kanters et al41 showed that myeloid IKK dele-
tion increased atherosclerosis in LDLR/ mice. NF-B
pro-survival function in macrophages may limit lesion
development in mouse models of atherosclerosis. Tar-
geted deletion of p50 in hematopoietic cells led to re-
duced atherosclerotic lesion formation in LDLR/
mice.42 These lesions exhibited a more inflammatory
phenotype, with relatively large numbers of T cells and B
cells. Surprisingly, lesions in these mice exhibited a
nearly complete absence of foam cells, likely because of
reduced endocytosis of lipoproteins and decreased ex-
pression of scavenger receptor class A. Interestingly,
overexpression of super-repressor of IB in macro-
phages decreased lipid ingestion by macrophage scav-
enger receptors and decreased foam-cell biogenesis.
Fang et al15 demonstrated that, in ApoE-p50-DKO mice,
CIH did not affect HDL-mediated cholesterol reverse
transport (there was no difference in hepatic ABCA1 and
SR-B1 expression) or the expression of SREBP-2 (which
is the master regulator of cholesterol synthesis), and did
not increase cholesterol synthesis. Hepatic LDL receptor
expression was reduced, however, and indeed the re-
duction of hepatic LDLR expression may be an important
component of the observed phenotype, one that merits
further investigation. Finally, these findings bear clinical
relevance, because persons with OSA have a higher
prevalence of dyslipidemia than those without OSA.43
Therapeutic Implications
NF-B has been implicated in many pathological states,
including autoimmune disease, cancer, cardiovascular
disease, and other metabolic disorders. It may be quite
attractive, therefore, to develop precisely engineered
drugs to counter these pathologies caused by NF-B
activation without affecting the potential beneficial func-
tions, particularly from p50. To date, several therapeutic
strategies aimed at selectively blocking NF-B activation
in animal models have involved i) biological agents (eg,
monoclonal antibodies) that reduce the activity of spe-
cific cytokines or their receptors, ii) small molecules that
disrupt lymphocyte trafficking, iii) inhibitors of kinases
(eg, IB kinase), iv) proteasome inhibitors to stabilize
IB, v) small peptides (eg, SN50) that target NF-B
nuclear translocation by inhibiting the nuclear import sys-
tem, vi) small molecules that inhibit specific NF-B DNA-protein binding to promoters, and vii) microRNAs that
reduce NF-B activity.44,45 Several biological agents
have been tested in clinical trials, including a humanized
monoclonal antibody that blocks the activation of CCR2
by CCL2 and also an IL-1 receptor antagonist, anakinra
(Kineret), which in 2001 was approved by the U.S. Food
and Drug Administration for the treatment of rheumatoid
arthritis. Treatment with IL-1 receptor antagonist also
reversed insulin resistance and glucose intolerance in
diabetes patients. Several agents that are able to inhibit
NF-B function are currently in clinical use as cancer
chemotherapeutics. The efficacy and specificity of sev-
eral rationally designed NF-B inhibitors are being tested
in a number of undergoing clinical trials. In the cardio-
vascular field, several widely used drugs have inhibitory
effects on NF-B activity or NF-B target gene expres-
sion; these include aspirin, salsalate (salicylsalicylic
acid), corticosteroids, and statins. Although neither inhib-
itors nor activators of specific NF-B pathways are yet
clinically available for use in cardiovascular disease, the
study by Fang et al15 provides important insights, includ-
ing the notion that inhibition of NF-B that preferentially
affects p50/p50 homodimers may have deleterious ef-
fects in the context of CIH and atherosclerosis.15 Given
the prevalence of dyslipidemia, metabolic syndrome, and
atherosclerosis in OSA subjects, augmenting the expres-
sion or function of NF-B p50 may provide new targets in
these high-risk individuals for cardiovascular disease.
Finally, the recruitment of coregulators to the p50/p50
homodimeric NF-B complex may have a particularly
important selective advantage for the modulation of CIH-
induced atherosclerosis. Understanding these events
may inform the generation of druggable targets in per-
sons with obstructive sleep apnea, atherosclerosis, or
chronic ischemic disease states.
References
1. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cock-
man ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour
suppressor protein VHL targets hypoxia-inducible factors for oxygen-
dependent proteolysis. Nature 1999, 399:271–275
2. Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases
that modify HIF. Science 2001, 294:1337–1340
3. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von
Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH,
Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel-
Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Science 2001, 292:468–472
4. van Uden P, Kenneth NS, Rocha S: Regulation of hypoxia-inducible
factor-1alpha by NF-kappaB. Biochem J 2008, 412:477–484
5. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet
V, Johnson RS, Haddad GG, Karin M: NF-kappaB links innate immu-
nity to the hypoxic response through transcriptional regulation of
HIF-1alpha. Nature 2008, 453:807–811
6. Eltzschig HK, Carmeliet P: Hypoxia and inflammation. N Engl J Med
2011, 364:656–665
7. Lurie A: Obstructive sleep apnea in adults: epidemiology, clinical
presentation, and treatment options. Adv Cardiol 2011, 46:1–42
8. Drager LF, Polotsky VY, Lorenzi-Filho G: Obstructive sleep apnea: an
emerging risk factor for atherosclerosis. Chest 2011, 140:534–542
9. Arnaud C, Dematteis M, Pepin JL, Baguet JP, Levy P: Obstructive
sleep apnea, immuno-inflammation, and atherosclerosis. Semin Im-
munopathol 2009, 31:113–125
NF-B and Hypoxia in Atherosclerosis 1517
AJP November 2012, Vol. 181, No. 510. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A,
Polotsky VY: Chronic intermittent hypoxia induces atherosclerosis.
Am J Respir Crit Care Med 2007, 175:1290–1297
11. Jun J, Reinke C, Bedja D, Berkowitz D, Bevans-Fonti S, Li J, Barouch
LA, Gabrielson K, Polotsky VY: Effect of intermittent hypoxia on ath-
erosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2010,
209:381–386
12. Arnaud C, Poulain L, Levy P, Dematteis M: Inflammation contributes
to the atherogenic role of intermittent hypoxia in apolipoprotein-E
knock out mice. Atherosclerosis 2011, 219:425–431
13. Arnaud C, Beguin PC, Lantuejoul S, Pepin JL, Guillermet C, Pelli G,
Burger F, Buatois V, Ribuot C, Baguet JP, Mach F, Levy P, Dematteis
M: The inflammatory preatherosclerotic remodeling induced by inter-
mittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am J Re-
spir Crit Care Med 2011, 184:724–731
14. Li RC, Haribabu B, Mathis SP, Kim J, Gozal D: Leukotriene B4
receptor-1 mediates intermittent hypoxia-induced atherogenesis.
Am J Respir Crit Care Med 2011, 184:124–131
15. Fang G, Song D, Ye X, Mao SZ, Liu G, Liu SF: Chronic intermittent
hypoxia exposure induces atherosclerosis in ApoE knockout mice:
role of NF-kappaB p50. Am J Pathol 2012, 181:1530–1539
16. Grundström S, Anderson P, Scheipers P, Sundstedt A: Bcl-3 and
NFkappaB p50-p50 homodimers act as transcriptional repressors in
tolerant CD4 T cells. J Biol Chem 2004, 279:8460–8468
17. Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J: The
NF-kappaB p50: p50:HDAC-1 repressor complex orchestrates tran-
scriptional inhibition of multiple pro-inflammatory genes. J Hepatol
2010, 53:519–527
18. Ashburner BP, Westerheide SD, Baldwin AS Jr: The p65 (RelA) sub-
unit of NF-kappaB interacts with the histone deacetylase (HDAC)
corepressors HDAC1 and HDAC2 to negatively regulate gene ex-
pression. Mol Cell Biol 2001, 21:7065–7077
19. Kumar A, Lin Z, SenBanerjee S, Jain MK: Tumor necrosis factor
alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by
NF-kappaB and histone deacetylases. Mol Cell Biol 2005, 25:5893–
5903
20. Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, Johnson
PF: Tumor necrosis factor alpha transcription in macrophages is
attenuated by an autocrine factor that preferentially induces NF-
kappaB p50. Mol Cell Biol 1998, 18:5678–5689
21. Tong X, Yin L, Washington R, Rosenberg DW, Giardina C: The p50-
p50 NF-kappaB complex as a stimulus-specific repressor of gene
activation. Mol Cell Biochem 2004, 265:171–183
22. Hirotani T, Lee PY, Kuwata H, Yamamoto M, Matsumoto M, Kawase I,
Akira S, Takeda K: The nuclear IkappaB protein IkappaBNS selec-
tively inhibits lipopolysaccharide-induced IL-6 production in macro-
phages of the colonic lamina propria. J Immunol 2005, 174:3650–
3657
23. Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S,
Mackman N, Ulevitch RJ: Regulation of an essential innate immune
response by the p50 subunit of NF-kappaB. J Clin Invest 1998,
102:1645–1652
24. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT,
Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J,
Taylor CT: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-
beta, giving insight into hypoxia-induced NFkappaB activity. Proc
Natl Acad Sci USA 2006, 103:18154–18159
25. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer
T, Sobolewski A, Condliffe AM, Cowburn AS, Johnson N, Chilvers ER:
Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-de-
pendent NF-kappaB activity. J Exp Med 2005, 201:105–115
26. Sha WC, Liou HC, Tuomanen EI, Baltimore D: Targeted disruption of
the p50 subunit of NF-kappa B leads to multifocal defects in immune
responses. Cell 1995, 80:321–330
27. Tomczak MF, Erdman SE, Davidson A, Wang YY, Nambiar PR, Rog-
ers AB, Rickman B, Luchetti D, Fox JG, Horwitz BH: Inhibition of
Helicobacter hepaticus-induced colitis by IL-10 requires the p50/
p105 subunit of NF-kappa B. J Immunol 2006, 177:7332–7339
28. Lu ZY, Yu SP, Wei JF, Wei L: Age-related neural degeneration in
nuclear-factor kappaB p50 knockout mice. Neuroscience 2006, 139:
965–97829. Yu Z, Zhou D, Cheng G, Mattson MP: Neuroprotective role for the p50
subunit of NF-kappaB in an experimental model of Huntington’s dis-
ease. J Mol Neurosci 2000, 15:31–44
30. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, Dieli F,
Ghisletti S, Natoli G, De Baetselier P, Mantovani A, Sica A: Tolerance
and M2 (alternative) macrophage polarization are related processes
orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA
2009, 106:14978–14983
31. Frantz S, Tillmanns J, Kuhlencordt PJ, Schmidt I, Adamek A, Dien-
esch C, Thum T, Gerondakis S, Ertl G, Bauersachs J: Tissue-specific
effects of the nuclear factor kappaB subunit p50 on myocardial
ischemia-reperfusion injury. Am J Pathol 2007, 171:507–512
32. Frantz S, Hu K, Bayer B, Gerondakis S, Strotmann J, Adamek A, Ertl
G, Bauersachs J: Absence of NF-kappaB subunit p50 improves heart
failure after myocardial infarction. FASEB J 2006, 20:1918–1920
33. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M,
Kaltschmidt C, Baeuerle PA, Neumeier D: Activated transcription
factor nuclear factor-kappa B is present in the atherosclerotic lesion.
J Clin Invest 1996, 97:1715–1722
34. Wilson SH, Caplice NM, Simari RD, Holmes DR Jr, Carlson PJ, Ler-
man A: Activated nuclear factor-kappaB is present in the coronary
vasculature in experimental hypercholesterolemia. Atherosclerosis
2000, 148:23–30
35. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI: The
NF-kappa B signal transduction pathway in aortic endothelial cells is
primed for activation in regions predisposed to atherosclerotic lesion
formation. Proc Natl Acad Sci USA 2000, 97:9052–9057
36. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, Cybulsky
MI: Patterns of vascular cell adhesion molecule-1 and intercellular
adhesion molecule-1 expression in rabbit and mouse atherosclerotic
lesions and at sites predisposed to lesion formation. Circ Res 1999,
85:199–207
37. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-
Ortega M, Egido J: Angiotensin-converting enzyme inhibition pre-
vents arterial nuclear factor-kappa B activation, monocyte chemoat-
tractant protein-1 expression, and macrophage infiltration in a rabbit
model of early accelerated atherosclerosis. Circulation 1997, 95:
1532–1541
38. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heim-
bürger O, Lindholm B, Stenvinkel P: Enhanced RAGE-mediated
NFkappaB stimulation in inflamed hemodialysis patients. Atheroscle-
rosis 2005, 180:333–340
39. Shah PK: Link between infection and atherosclerosis: who are the
culprits: viruses, bacteria, both, or neither? Circulation 2001, 103:5–6
40. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ,
Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M:
Endothelial cell-specific NF-kappaB inhibition protects mice from ath-
erosclerosis. Cell Metab 2008, 8:372–383
41. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hen-
driks I, Fijneman RJ, Clausen BE, Förster I, Kockx MM, Rajewsky K,
Kraal G, Hofker MH, de Winther MP: Inhibition of NF-kappaB activa-
tion in macrophages increases atherosclerosis in LDL receptor-defi-
cient mice. J Clin Invest 2003, 112:1176–1185
42. Kanters E, Gijbels MJ, van der Made I, Vergouwe MN, Heeringa P,
Kraal G, Hofker MH, de Winther MP: Hematopoietic NF-kappaB1
deficiency results in small atherosclerotic lesions with an inflamma-
tory phenotype. Blood 2004, 103:934–940
43. Drager LF, Jun J, Polotsky VY: Obstructive sleep apnea and
dyslipidemia: implications for atherosclerosis [Erratum appeared in
Curr Opin Endocrinol Diabetes Obes 2010, 17:394]. Curr Opin En-
docrinol Diabetes Obes 2010, 17:161–165
44. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM,
Vera MP; MICU Registry, Blackwell TS, Baron RM, Feinberg MW:
MicroRNA-181b regulates NF-kappaB-mediated vascular inflamma-
tion. J Clin Invest 2012, 122:1973–1990
45. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF: MicroRNA-10a
regulation of proinflammatory phenotype in athero-susceptible endo-
thelium in vivo and in vitro. Proc Natl Acad Sci USA 2010, 107:13450–
13455
